share_log

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K：重大事件
美股SEC公告 ·  2024/11/23 06:01

Moomoo AI 已提取核心訊息

Elevai Labs Inc. announced a 1-for-200 reverse stock split effective November 27, 2024, aimed at maintaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The split was approved by stockholders on August 12, 2024, and the board of directors on August 22, 2024.Under the split terms, every 200 shares of common stock will automatically consolidate into one share, with stockholders receiving one whole share in lieu of fractional shares. The company's trading symbol remains "ELAB" but with a new CUSIP number (28622K 203). Post-split, approximately 3.07 million shares of common stock will be outstanding.The company has adjusted its equity incentive plan, including the number of shares available for future grants and the exercise prices of outstanding stock options. VStock Transfer, LLC will serve as the exchange agent, though stockholders holding shares in brokerage accounts require no action. The move is part of Elevai's strategy to maintain Nasdaq listing compliance and enhance market visibility.
Elevai Labs Inc. announced a 1-for-200 reverse stock split effective November 27, 2024, aimed at maintaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The split was approved by stockholders on August 12, 2024, and the board of directors on August 22, 2024.Under the split terms, every 200 shares of common stock will automatically consolidate into one share, with stockholders receiving one whole share in lieu of fractional shares. The company's trading symbol remains "ELAB" but with a new CUSIP number (28622K 203). Post-split, approximately 3.07 million shares of common stock will be outstanding.The company has adjusted its equity incentive plan, including the number of shares available for future grants and the exercise prices of outstanding stock options. VStock Transfer, LLC will serve as the exchange agent, though stockholders holding shares in brokerage accounts require no action. The move is part of Elevai's strategy to maintain Nasdaq listing compliance and enhance market visibility.
Elevai Labs Inc. 宣佈將於2024年11月27日進行1比200的反向股拆分，此舉旨在保持符合納斯達克每股最低買盤價格要求1.00美元的標準。該拆分於2024年8月12日獲得股東批准，並於2024年8月22日獲得董事會批准。根據拆分條款，每200股普通股將自動合併爲一股，股東將收穫一整股以替代碎股。公司的交易標的保持爲 "ELAB"，但會有一個新的CUSIP號碼（2862.2萬 203）。拆分後，約307萬股普通股將流通在外。公司已調整其股權激勵計劃，包括未來授予的可用股份數量及已發行期權的行使價格。VStock Transfer, LLC 將擔任交易所代理，持有券商賬戶股份的股東無需採取任何行動。這一舉措是Elevai保持納斯達克上市合規性並提升市場可見性策略的一部分。
Elevai Labs Inc. 宣佈將於2024年11月27日進行1比200的反向股拆分，此舉旨在保持符合納斯達克每股最低買盤價格要求1.00美元的標準。該拆分於2024年8月12日獲得股東批准，並於2024年8月22日獲得董事會批准。根據拆分條款，每200股普通股將自動合併爲一股，股東將收穫一整股以替代碎股。公司的交易標的保持爲 "ELAB"，但會有一個新的CUSIP號碼（2862.2萬 203）。拆分後，約307萬股普通股將流通在外。公司已調整其股權激勵計劃，包括未來授予的可用股份數量及已發行期權的行使價格。VStock Transfer, LLC 將擔任交易所代理，持有券商賬戶股份的股東無需採取任何行動。這一舉措是Elevai保持納斯達克上市合規性並提升市場可見性策略的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Dogwood Therapeutics
    DWTX
    -- 14.680
    Transcode Therapeutics
    RNAZ
    -- 9.180
    Hepion Pharmaceuticals
    HEPA
    -- 0.2187
    Nutriband
    NTRB
    -- 10.385
    Renovaro
    RENB
    -- 1.030
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    中美談話新契機，通脹不再？
    🎙️討論： 1. 特朗普上台後，對華政策如何影響中國資產？ 2. 美股市場通脹風險下降，哪些板塊受益？ 展开
    中國將在明年採取 “適度寬鬆” 的貨幣政策，這是自2011年以來首次轉向寬鬆